Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States
Transplantation and Cellular Therapy
Open Access Publication
Rights and Permissions
Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. Transplant Cell Ther. 2022 Sep;28(9):581.e1-581.e8. doi: 10.1016/j.jtct.2022.05.026. © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Jacobson, Caron A; Ghobadi, Armin; and et al., "Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States." Transplantation and Cellular Therapy. 28, 9. 581.e1 - 581.e8. (2022).
ICTS (Institute of Clinical and Translational Sciences)
Supplemental material is available for this article at publisher site.